La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Neurocrine Biosciences Crescita futura

Future criteri di controllo 5/6

Neurocrine Biosciences prevede che gli utili e i ricavi cresceranno rispettivamente di 29.4% e 14.2% all'anno. Si prevede che l'EPS crescerà di 28.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 26.8% in 3 anni.

Informazioni chiave

29.4%

Tasso di crescita degli utili

28.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.3%
Tasso di crescita dei ricavi	14.2%
Rendimento futuro del capitale proprio	26.8%
Copertura analitica	Good
Ultimo aggiornamento	19 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:NBIX - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	3,182	963	917	1,002	18
12/31/2025	2,699	704	746	824	23
12/31/2024	2,333	454	582	567	21
6/30/2024	2,120	339	495	530	N/A
3/31/2024	1,982	370	614	645	N/A
12/31/2023	1,887	250	362	390	N/A
9/30/2023	1,784	191	385	409	N/A
6/30/2023	1,673	176	281	296	N/A
3/31/2023	1,599	64	237	255	N/A
12/31/2022	1,489	155	323	339	N/A
9/30/2022	1,389	58	177	201	N/A
6/30/2022	1,297	12	133	164	N/A
3/31/2022	1,208	71	102	129	N/A
12/31/2021	1,134	90	233	257	N/A
9/30/2021	1,069	445	328	347	N/A
6/30/2021	1,032	365	251	265	N/A
3/31/2021	1,045	402	266	280	N/A
12/31/2020	1,046	407	218	229	N/A
9/30/2020	1,042	93	222	232	N/A
6/30/2020	1,006	205	337	350	N/A
3/31/2020	887	177	283	295	N/A
12/31/2019	788	37	132	147	N/A
9/30/2019	675	21	82	100	N/A
6/30/2019	605	18	44	71	N/A
3/31/2019	519	-39	0	27	N/A
12/31/2018	451	21	77	101	N/A
9/30/2018	414	10	70	91	N/A
6/30/2018	323	-52	2	13	N/A
3/31/2018	233	-106	N/A	-55	N/A
12/31/2017	162	-143	N/A	-94	N/A
9/30/2017	67	-194	N/A	-167	N/A
6/30/2017	6	-220	N/A	-188	N/A
3/31/2017	N/A	-200	N/A	-154	N/A
12/31/2016	15	-141	N/A	-106	N/A
9/30/2016	15	-126	N/A	-90	N/A
6/30/2016	15	-123	N/A	-77	N/A
3/31/2016	15	-107	N/A	-49	N/A
12/31/2015	20	-89	N/A	-38	N/A
9/30/2015	20	-79	N/A	-38	N/A
6/30/2015	20	-60	N/A	-32	N/A
3/31/2015	20	-50	N/A	-56	N/A
12/31/2014	N/A	-61	N/A	-47	N/A
9/30/2014	1	-52	N/A	-43	N/A
6/30/2014	1	-47	N/A	-41	N/A
3/31/2014	2	-46	N/A	-41	N/A
12/31/2013	3	-46	N/A	-30	N/A
9/30/2013	24	-26	N/A	-28	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di NBIX ( 29.4% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di NBIX ( 29.4% all'anno) cresceranno più rapidamente del mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di NBIX cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di NBIX ( 14.2% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di NBIX ( 14.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di NBIX sarà elevato tra 3 anni ( 26.8 %)

Neurocrine Biosciences Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 7.0% to US$172

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Recent updates

Price target increased by 7.0% to US$172

Independent Chairman of the Board recently sold US$2.1m worth of stock

Independent Director exercised options and sold US$1.2m worth of stock

Chief Human Resources Officer exercised options and sold US$1.2m worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease